Neurochem successfully closed its first public offering on June 22, 2000. The Company was officially listed on that day on the Toronto Stock Exchange under the symbol "NRM".   (NRM.TO)

Neurochem successfully closed its second public offering and was officially registered on September 23, 2003 on NASDAQ. The Company is now listed under the symbol "NRMX". (NASDAQ;NRMX).



Annual Meeting


The Annual and Special Meeting of Shareholders will be held at 10:00 A.M. on April 15, 2008, in the Maxwell Cummings Auditorium of the Michal and Renata Hornstein Pavilion of the Montreal Museum of Fine Arts, located at 1379 Sherbrooke Street West, Montreal, Quebec.




Annual Reports:


Annual Report 2007

       - Management's discussion and analysis of consolidated
          financial condition and result of operations.

       - Financial statements


Annual Report 2006

       - Management's discussion and analysis of consolidated
          financial condition and result of operations.

       - Financial statements


Annual Report 2005

       - Management's discussion and analysis of consolidated
          financial condition and result of operations.

       - Financial statements


Annual Report 2004

       - Management's discussion and analysis of consolidated
          financial condition and result of operations.

       - Financial statements


Annual Report 2003

Annual Report 2002

Annual Report 2001

Annual Report 2000


www.sedar.com

Back to the top




Quarterly Reports:


Year ending December 31, 2007

  - Third quarter ended September 30, 2007

  - Second quarter ended June 30, 2007

  - First quarter ended March 31, 2007


Year ended December 31, 2006

  - Third quarter ended September 30, 2006

  - Second quarter ended June 30, 2006

  - First quarter ended March 31, 2006


Year ended December 31, 2005

  - Third quarter ended September 30, 2005

  - Second quarter ended June 30, 2005

  - First quarter ended March 31, 2005


Archived Quarterly Reports


www.sedar.com

Back to the top




Analysts:


In Canada

David Dean

Cormark Securities Inc.
ddean@cormark.com

Analyst to be determined

Loewen, Ondaatje, McCutcheon Limited

Philippa Flint

RBC Capital Markets
philippa.flint@rbccm.com

In the United States

Brian Lian

CIBC World Markets
Brian.Lian@us.cibc.com

Patrick Moriarty

Fortis Securities LLC
patrick.moriarty@us.fortis.com

Elemer Piros

Rodman & Renshaw
epiros@rodmanandrenshaw.com


Back to the top




Neurochem in the news:

Some of the latest articles on Neurochem's achievements, in general and scientific publications:

New England Journal of Medicine

356:2349, June 7, 2007
"Eprodisate for the treatment of Renal Disease in AA Amyloidosis"
To receive a reprint


Neurobiology of Aging

Volume 28, Issue 4, April 2007
"Targeting soluble Aß peptide with Tramiprosate for the treatment of brain amyloidosis"
To receive a reprint


Neurology

November 2006, vol. 67, no. 10
"A Phase II study targeting amyloid-ß with 3APS in mild-to-moderate Alzheimer disease"
To receive a reprint


Medical Marketing & Media

August 2006
"The Age of Alzheimer’s"

Newsweek

Summer 2005, Your Health Special Edition
"7 Ways to Save a Brain"

Nature

August 2004, vol.430
"Pathways towards and away from Alzheimer's Disease"


BioWorld Today

August 12, 2004, vol.15, no.155
"Mouse Model Confirms Role of Amyloid in Alzheimer's Disease"


Reuters Health

August 6, 2004
"New Study Offers Hope for Alzheimer's Treatment"


Neuron

August 5, 2004
"Aß Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome."
To receive a reprint


Script Report

July 2004
"Novel Approaches to Alzheimer's Disease"


The Wall Street Journal

June 29, 2004
"A New Approach to Fighting Alzheimer's"


Commerce

March 2004 (P.74)
Dossier financement: "Vaincre l'Alzheimer"


Biotechnology Focus

February 2004, Vol. 7, No. 2 (pp. 17-20)
"Ambitious Biopharma"


Back to the top




Transfer agent:

Computershare Investor Services

100 University Avenue,
9th Floor
Toronto, Ontario
M5J 2Y1
Tel: (514) 982-7555
       1-800-564-6253

Auditors:

KMPG L.L.P.

600, De Maisonneuve Blvd. West
Suite 1500
Montreal, Quebec
H3A 0A3

Back to the top




For further information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
275 Armand-Frappier Blvd.
Laval, Quebec,
Canada, H7V 4A7

Tel : (450) 680-4500
Fax : (450) 680-4501
Email: ir@neurochem.com
or: webinfo@neurochem.com

Our site is best viewed with IE4+ at a resolution of 1024×768.
Tout contenu, copyright © 1998-2007 Neurochem Inc.
Terms, Conditions and Legal Notice.